sponsored
PatientsVille.com Logo

PatientsVille

Conray Medical Research Studies

Up-to-date List of Conray Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Conray Medical Research Studies

Rank Status Study
1 Recruiting Kidney Disease Biomarkers
Conditions: Kidney Disease;   Glomerular Disease;   Idiopathic Nephrotic Syndrome;   Focal Segmental Glomerulosclerosis;   Collapsing Glomerulopathy
Intervention:
Outcome Measure:
2 Recruiting Assessment of Renal Function in Cirrhotic Patients
Conditions: Liver Failure;   Renal Failure
Intervention:
Outcome Measure: Creatinine based blood and urine laboratory tests as a measure of renal function in patients with chirrosis of the liver.
3 Unknown  Comparative Renal Function of Young (18-45 Years) and Ageing (55 Years and Above) Kidney Donors
Condition: Kidney Diseases
Interventions: Procedure: CT angiogram of the remaining kidney.;   Procedure: Kidney Function study using Iothalamate & PAH as clearance markers
Outcome Measures: Diminished adaptive response to living kidney donation in ageing donors as compared to living donors.;   Renal Failure & new onset, or worsening, of hypertension in living kidney donors
4 Recruiting Study to Assess the Effects of Intravenous Bendavia in Patients Undergoing Percutaneous Transluminal Angioplasty of the Renal Artery (PTRA)
Conditions: Renal Artery Obstruction;   Hypertension, Renovascular;   Ischemia Reperfusion Injury
Interventions: Drug: Bendavia;   Drug: Placebo
Outcome Measures: Comparison between treatment groups in the change in the glomerular filtration rate (GFR), as measured by iothalamate clearance, from before percutaneous renal artery angioplasty (PTRA) to 8 weeks post-PTRA.;   Mean change in renal volume (ml) as measured using Multi-Detector Computed Tomography (MDCT) from pre-PTRA to 8 weeks post-PTRA with and without Bendavia.;   Mean change in regional perfusion (medulla) (ml/minute/ml of tissue) as measured using Multi-Detector Computed Tomography (MDCT) from pre-PTRA to 8 weeks post-PTRA with and without Bendavia.;   Mean change in regional perfusion (cortex) (ml/minute/ml of tissue) as measured using Multi-Detector Computed Tomography (MDCT) from pre-PTRA to 8 weeks post-PTRA with and without Bendavia.;   Mean change in glomerular flow rate (ml/minute) as measured using Multi-Detector Computed Tomography (MDCT) from pre-PTRA to 8 weeks post-PTRA with and without Bendavia.;   Mean change in renal blood flow (ml/minute) as measured using Multi-Detector Computed Tomography (MDCT) from pre-PTRA to 8 weeks post-PTRA with and without Bendavia.;   Mean change in renal oxygenation between pre-PTRA, 27 hours post-PTRA and 8 weeks post-PTRA as measured by calculation of fractional hypoxia using blood oxygenation level-dependent magnetic resonance (BOLD-MR) imaging, with and without Bendavia.;   Mean change in plasma 8-isoprostane (8-iso prostaglandin F2-alpha) levels (pg/ml) from pre-PTRA and then immediately post-PTRA and 8 weeks post-PTRA, with and without Bendavia.;   Mean change in Monocyte Chemotactic Protein-1 (MCP-1) levels (pg/ml) from pre-PTRA and then immediately post-PTRA and 8 weeks post-PTRA, with and without Bendavia.;   Mean change in Tumor Necrosis Factor-alpha (TNF-a) levels (pg/ml) from pre-PTRA and then immediately post-PTRA and 8 weeks post-PTRA, with and without Bendavia.;   Mean change in Interferon-Gamma (IFN-gamma) levels (pg/ml) from pre-PTRA and then immediately post-PTRA and 8 weeks post-PTRA, with and without Bendavia.;   Mean change in Interleukin-10 (IL-10) levels (pg/ml) from pre-PTRA and then immediately post-PTRA and 8 weeks post-PTRA, with and without Bendavia.;   Mean change in Neutrophil Gelatinase-Associated Lipocalin (NGAL) levels (pg/ml) from pre-PTRA to immediately post-PTRA, 3, 9, 15, 21, and 27 hours post-PTRA and then 8 weeks post-PTRA, with and without Bendavia.;   Mean change in High Sensitivity C-Reactive Protein (hs-CRP) levels (mg/L) from pre-PTRA to immediately post-PTRA and 15 hours, 27 hours and 8 weeks post-PTRA, with and without Bendavia.;   Mean change in partial pressure of blood oxygen (PO2) values (mmHg) from pre-PTRA and then immediately post-PTRA and 8 weeks post-PTRA, with and without Bendavia.;   Mean change in Plasma Renin Activity (PRA) levels (ng/ml/hr) from pre-PTRA and then immediately post-PTRA and 8 weeks post-PTRA, with and without Bendavia.;   Mean Change in Systolic Blood Pressure (SBP) values (mmHg) from pre-PTRA, immediately post-PTRA, 27 hours and 8 weeks post-PTRA, with and without Bendavia.;   Mean Change in Diastolic Blood Pressure (DBP) values (mmHg) from pre-PTRA, immediately post-PTRA, 27 hours and 8 weeks post-PTRA, with and without Bendavia.;   Number of adverse events observed with and without Bendavia;   Mean change in serum sodium levels (mmol/l) from pre-study drug administration (and pre-PTRA), and then at 3, 9, 15, 21, and 27 hours post-PTRA, with and without Bendavia.;   Mean change in urine sodium levels (mmol/l) from pre-study drug administration (and pre-PTRA), and then at 3, 9, 15, 21, and 27 hours post-PTRA, with and without Bendavia.;   Mean change in serum osmolality levels (mOsm/kg) from pre-study drug administration (and pre-PTRA), and then at 3, 9, 15, 21, and 27 hours post-PTRA, with and without Bendavia.;   Mean change in urine osmolality levels (mOsm/kg) from pre-study drug administration (and pre-PTRA), and then at 3, 9, 15, 21, and 27 hours post-PTRA, with and without Bendavia.;   Mean change in plasma Arginine Vasopressin (AVP) levels (pg/ml) from pre-study drug administration (and pre-PTRA), and then at 3, 9, 15, 21, and 27 hours post-PTRA , with and without Bendavia.;   Mean difference in Bendavia Area Under the Curve(0-infinity) (AUC) when Bendavia is administered in patients undergoing PTRA and healthy volunteers (historical data will be used to provide AUC for Bendavia in healthy volunteers).
5 Recruiting An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction
Conditions: Healthy Volunteers,;   Chronic Renal Insufficiency
Interventions: Drug: LHW090;   Drug: Placebo
Outcome Measures: Number of participants (Healthy Volunteers) with reported adverse events receiving single oral dose of LHW090 as assessment of safety and tolerabiility;   Number of participants (Healthy Volunteers) with reported adverse events receiving multiple oral dose of LHW090 as assessment of safety and tolerabiility;   Number of participants (patients) with reported adverse events receiving single oral dose of LHW090 as assessment of safety and tolerabiility;   Pharmacokinetics of LHW090/LHV527 in plasma: observe maximum plasma concentration following LHW090 at steady state in healthy volunteers and patients;   Pharmacokinetics of LHW090/LHV527 in plasma: time to reach the maximum concentration after administration of LHW090 (Tmax);   Pharmacokinetics of LHW090/LHV527 in plasma: area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUClast);   Pharmacokinetics of LHW090/LHV527 in plasma: area under the plasma concentration-time curve from time zero to infinity (AUCinf);   Pharmacokinetics of LHW090/LHV527 in plasma: terminal elimination half-life (T1/2);   Pharmacokinetics of LHW090/LHV527 in plasma: accumulation ratio (RACC);   Pharmacokinetics of LHW090/LHV527 in plasma: apparent volume of distribution during the terminal elimination phase following extravascular administration (Vd/F);   Pharmacokinetics of LHW090/LHV527 in plasma: apparent system clearance from plasma following intravenous administration of iothalamate (CL/F);   Pharmacokinetics of LHW090/LHV527 in urine: apparent system clearance from urine from time 0 - 24 hrs following drug administration (Ae0-24);   Pharmacokinetics of LHW090/LHV527 in urine: apparent system clearance from urine from time 0 - 72 hrs following drug administration (Ae0-72h);   Pharmacokinetics of LHW090/LHV527 in urine: apparent renal clearance from urine following drug administration (CLr);   Pharmacodynamics of LHW090/LHV527 in serum: post treatment peak and mean area under the plasma concentration-time curve from time zero to 24 hour (AUC0-24h/24h) for cyclic guanosine (cGMP);   Pharmacodynamics of LHW090/LHV527 in serum: post treatment peak and mean area under the plasma concentration-time curve from time zero to 24 hour (AUC0-24h/24h) for atrial natriuretic peptide (ANP)
6 Recruiting Cause of Focal Segmental Glomerulosclerosis
Conditions: AIDS Associated Nephropathy;   Focal Glomerulosclerosis;   HIV Infections
Intervention:
Outcome Measure:

These studies may lead to new treatments and are adding insight into Conray etiology and treatment.

A major focus of Conray research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Conray